Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer

Mucositis
DOI: 10.1097/coc.0b013e31827e52a3 Publication Date: 2013-03-05T14:10:21Z
ABSTRACT
To evaluate toxicity, local control, and survival in anal cancer patients treated with intensity-modulated radiation therapy (IMRT) concurrent chemotherapy.Sixty-five were at a single institution IMRT chemotherapy for localized squamous cell carcinoma of the canal. Radiotherapy was delivered simultaneous integrated boost technique, dose based on T stage. The median to primary tumor pelvis 54 Gy (range, 50 58.8 Gy) 45 40.5 50.4 Gy), respectively. most common regimens 5-fluorouracil cisplatin (75%), capecitabine oxaliplatin (11%), mitomycin C (5%).The percentage Tx, T1, T2, T3, T4 disease 8%, 17%, 49%, 15%, 11%, N0, N1, N2, N3 46%, 9%, 28%, Ninety-one percent completed treatment without break. Grade 3 gastrointestinal toxicity occurred moist desquamation beyond perianal area 17%. use vaginal dilator during simulation seemed lower rates acute skin late sexual toxicity. With follow-up 19 months, 2-year distant control both 93%. overall disease-free 96% 86%, respectively.Concurrent well tolerated, associated low excellent survival, survival.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (15)
CITATIONS (51)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....